Partners

  • Corey Goodman Corey Goodman, PhD
  • Kurt von Emster Kurt von Emster, CFA
  • Paul Brooke Paul Brooke
  • Robert Adelman Robert Adelman, MD
  • Behzad Aghazadeh Behzad Aghazadeh, PhD
  • Corey Goodman, PhD

    Corey Goodman, PhD is a Managing Partner of venBio. Dr. Goodman is a renowned scientist, entrepreneur, educator, CEO, and corporate executive. He was formerly President of Pfizer Inc.'s Biotherapeutics and Bioinnovation Center, and a member of Pfizer's Executive Leadership Team. Dr. Goodman co-founded Exelixis, Renovis, Second Genome, Ossianix, Labrys Biologics, and Solstice Biologics, and was CEO of Renovis until its acquisition by Evotec. He is a former professor at Stanford University and UC Berkeley, co-founder of Berkeley's Wills Neuroscience Institute, Investigator with the Howard Hughes Medical Institute, and currently Adjunct Professor at UC San Francisco. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, among others, the Alan T. Waterman Award from the National Science Board, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Trinity College Dublin Dawson Prize in Genetics. He is on the Board of the California Council on Science and Technology, the Pacific Institute, and former chair of the National Academy of Sciences' Board on Life Sciences. He is an advisor to several university innovation centers and disease foundations. He is Chairman of the Board of several companies, including Solstice Biologics, Labrys Biologics, Oligasis, Ossianix, and Second Genome, and a member of the Board of Mirna Therapeutics. Dr. Goodman is located in venBio's San Francisco office.

  • Kurt von Emster, CFA

    Kurt von Emster, CFA has been an institutional biotechnology and health care analyst and portfolio manager for over 20 years. Mr. von Emster is a Managing Partner of venBio. He is a member of the board of directors of Cytos AG and CymaBay Therapeutics, Inc., a former member of the board of Somaxon Pharmaceuticals Inc. (sold to Pernix Therapeutics in 2013) and Facet Biotech Corporation (sold to Abbott Laboratories in 2010), and a former board observer of Acceleron Pharma. Mr. von Emster's investment career started in 1989 at Franklin Templeton where he founded and managed several health and biotechnology funds in the 1990s, each achieving a 5-star Morningstar ranking. In 2000, he was managing over $2B in biotech and health care funds for Franklin Templeton. In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. He also co-founded the MPM Biogen Idec Strategic Fund during his tenure at MPM. Mr. von Emster is located in the San Francisco office.

  • Paul Brooke

    Paul Brooke is a Managing Partner of venBio. Mr. Brooke has over 30 years' experience in life science analysis, investing and management. He is Director of ViroPharma Incorporated, Incyte Corporation, Cytos AG, Cheyne Capital International Ltd and Manning & Napier. Mr. Brooke was an advisor to MPM Capital and a Member of the Board of Directors of the MPM Bio Equities Fund. He was the Global Head of Health Care Research and Strategy for Morgan Stanley and headed up Strategy and Economics for the Pacific Basin including Japan. Mr. Brooke was also a Managing Director of Tiger Management responsible for health care investing. Through his role as Chairman and CEO of Ithaka, he structured the purchase of Alsius Corporation and successfully sold its assets to Zoll Medical Corporaton in 2008. Mr. Brooke is located in venBio's New York office.

  • Robert Adelman, MD

    Robert Adelman, M.D. is a Managing Partner of venBio. Dr. Adelman has a 26-year history of founding, investing in, and managing companies in the life sciences. Before joining venBio, he had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both public and private companies across three venture capital funds. Dr. Adelman has founded a number of biotechnology companies including Operon Technologies Inc. (sold to Qiagen Inc. in 2000), Sientra Inc., and most recently Roka Bioscience (a spin out of Gen-Probe). Dr. Adelman has served on the Boards of Aragon Pharmaceuticals, Inc. (sold to Johnson & Johnson in 2013), Volcano Corporation, Aryx Therapeutics Inc., Cerimon Pharmaceuticals Inc., and ViewRay Incorporated. In addition, he currently serves on the Board of Directors of Seragon Pharmaceuticals and Solstice Biologics. Dr. Adelman is located in the San Francisco office.

  • Behzad Aghazadeh, PhD

    Behzad Aghazadeh, PhD is a Partner of venBio and Portfolio Manager of the venBio Select Fund. Dr. Aghazadeh has over 16 years of experience in the healthcare sector as an investor, management consultant, and research scientist. Before joining venBio, Dr. Aghazadeh was a Partner and Senior Analyst with Sio Capital Management, a New York-based global long/short equity healthcare fund. Previously, Dr. Aghazadeh was a Vice President and Senior Analyst with Bernstein Value Equities, the asset management business of AllianceBernstein. At Bernstein, Dr. Aghazadeh was responsible for global coverage of pharmaceutical, biotech, medtech and managed care companies and led the healthcare investments in 5 of its U.S. and international portfolios that comprised $350B of the firm's assets. Prior to Bernstein, Dr. Aghazadeh was a Principal in the healthcare practice of Booz Allen (now Booz & Co.). During his six year tenure, Dr. Aghazadeh served corporate executive clients across healthcare verticals and led teams on strategic and operations issues. He also led a program for the US Food and Drug Administration's drug review divisions on a Congress mandated assessment to enhance the productivity of the drug review and approval process. Dr. Aghazadeh was co-lead of Booz Allen's Pharma R&D effectiveness platform. Dr. Aghazadeh has extensive research experience, including at Memorial Sloan-Kettering (Howard Hughes Laboratory of Signal Transduction and Structural Biology, Laboratory of Magnetic Resonance Imaging) and Ludwig-Maximilians University (Laboratory of Thermodynamics and Materials Sciences). He has published numerous peer-reviewed papers in leading journals including Cell and Nature. Dr. Aghazadeh received a PhD in Biophysics and Biochemistry from Cornell University, and a Masters in Physics from the Ludwig-Maximilians-University in Munich, Germany. He is fluent in English, German and Farsi. Dr. Aghazadeh is located in venBio's New York office.